Vericel Corporation $VCEL Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC cut its position in shares of Vericel Corporation (NASDAQ:VCEL) by 7.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 138,630 shares of the biotechnology company’s stock after selling 11,895 shares during the period. Segall Bryant & Hamill LLC’s holdings in Vericel were worth $4,460,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new position in shares of Vericel in the fourth quarter worth about $27,000. Quarry LP purchased a new position in shares of Vericel in the 4th quarter valued at about $31,000. Farther Finance Advisors LLC increased its stake in shares of Vericel by 116.5% in the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 522 shares in the last quarter. Truvestments Capital LLC raised its holdings in Vericel by 175.4% in the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 977 shares during the period. Finally, Empowered Funds LLC purchased a new position in Vericel during the fourth quarter worth approximately $58,000.

Insider Transactions at Vericel

In other Vericel news, insider Jonathan Siegal sold 4,500 shares of Vericel stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total transaction of $220,050.00. Following the sale, the insider owned 1,078 shares of the company’s stock, valued at $52,714.20. The trade was a 80.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of Vericel stock in a transaction on Friday, June 26th. The stock was sold at an average price of $44.75, for a total transaction of $223,750.00. Following the sale, the chief financial officer directly owned 16,009 shares in the company, valued at approximately $716,402.75. This trade represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 52,232 shares of company stock worth $2,304,217. Company insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on VCEL shares. TD Cowen boosted their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday. Canaccord Genuity Group set a $60.00 price target on shares of Vericel in a research note on Thursday. Truist Financial reissued a “buy” rating and issued a $58.00 price target (up from $54.00) on shares of Vericel in a report on Friday. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Vericel in a research report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of Vericel from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and a consensus target price of $58.40.

Vericel Trading Up 0.2%

NASDAQ:VCEL opened at $46.05 on Tuesday. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $49.32. The stock has a 50 day moving average of $42.18 and a two-hundred day moving average of $37.46. The firm has a market cap of $2.36 billion, a P/E ratio of 97.98 and a beta of 1.06.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The business had revenue of $77.46 million for the quarter, compared to the consensus estimate of $72.70 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.01) earnings per share. On average, research analysts forecast that Vericel Corporation will post 0.49 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.